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Abstract
Background: MicroRNAs (miRNAs) regulate the expression of genes involved in various cellular functions related to
metabolism, inflammation, and reproduction. This study evaluated the effects of sex hormones and obesity on the
expression of circulating miR-23a and miR-23b in women with polycystic ovary syndrome (PCOS) and healthy women.
Methods: Serum sex hormones concentrations and body mass index (BMI) were measured in 18 women with PCOS
and in 30 healthy women from the East China area and these measurements were correlated with serum miR-23a/b
levels. The effect of miR-23a and miR-23b risk factors on occurrence of PCOS and predisposing factors of PCOS on
these miRNA expressions were evaluated.
Results: The expressions of miR-23a/b were significantly lower in the women with PCOS than the normal women, and
the expression levels of miR-23a/b were positively correlated with each other in the normal women (p = 0.001) but not
in the women with PCOS (p > 0.05). In the women with PCOS, miR-23a was positively correlated with BMI (p = 0.03).
However, no correlations were found between the levels of miR-23a/b and the sex hormones in the normal and PCOS
women. On the other hand, without considering the presence or absence of PCOS, increase in BMI had a positive
effect on the levels of circulating miR-23b; while testosterone had negative effects on the levels of circulating miR-23a.
Furthermore, the likelihood of women with PCOS decreased by 0.01-fold for every 1 fold increase of miR-23a expression.
Conclusions: Both reduced levels and discordance between the expressions of miR-23a/b were observed in the women
with PCOS and miR-23a/b were affected from testosterone and BMI, reversely. Therefore, miR-23a alteration in contrast
with miR-23b is a better indicator for evaluation of PCOS than the miR-23b.
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Background
Polycystic ovary syndrome (PCOS) is one of the most
common reproductive, endocrine, and metabolic disor-
ders in women. It affects about 5 to 10% of women of
reproductive age and is usually a lifelong disease. PCOS
is characterized by chronic anovulation, hyperandrogen-
ism, and, consequently, infertility [1]. Metabolic disor-
ders, including obesity, insulin resistance, and diabetes,
are cofactors as well as predisposing factors of PCOS
[2]. Therefore, understanding the molecular mechanisms
of the metabolic diseases underlying the pathophysiology
of PCOS will help to identify novel diagnostic and thera-
peutic strategies.
Previously, it was shown that microRNAs (miRNAs)
play an important role in follicular development and fer-
tility [3]. The miRNAs are highly conserved, 19 to 25
nucleotide-long, single-stranded RNA molecules that
post-transcriptionally regulate gene expression, and they
perform their functions by mediating translational
repression or by directing the cleavage of target mRNAs.
Recent evidence suggests that miRNAs play fundamental
roles in all cellular and tissue activities under both nor-
mal and pathological conditions, but the currently avail-
able information on the expression and function of
miRNAs in the ovary, especially in oocyte development,
is still very limited. It was discovered, however, that
miRNAs might be involved in the turnover of many ma-
ternal transcripts whose degradation might be essential
for the successful completion of meiotic maturation by
oocytes [3].
The analysis of expression of miR-23a and miR-23b in
follicular cells from women undergoing assisted repro-
ductive technology (ART) including the patients with
tubal factor and endometriosis showed that significant
increase in the levels of miR-23b directly correlated with
CYP19A1 (aromatase gene) expression, miR-23a, com-
pared to normal women [4]. Aromatase which convert
androgens to estrogen has role in pathogenesis of PCOS
[5]. Therefore, in the present study, serum samples and
other information were collected from women with
PCOS and healthy controls to study the correlation
between serum miR-23a/b expression, obesity, and sex
hormones in women with PCOS.
Results
Expression of miR-23a/b in controls and PCOS patients
The expression of miR-23a and miR-23b was down-
regulated in the women with PCOS compared to the
healthy controls (Cv = 73.2, p = 0.008, and Cv = 93.3,
p = 0.04, respectively, Fig. 1a and b). Comparison of
the healthy women according to the different phases
of the endometrial cycle (proliferative, early secretory,
Fig. 1 Serum miRNA-23a (a) and miRNA-23b (b) expression in normal women, polycystic ovary syndrome (PCOS) patients, and normal women at
different stages of the menstrual cycle. a,b different superscript letters indicate significant differences between groups (p < 0.05). Correlation between
serum miRNA-23a and miRNA-23b expression in normal women (c) and PCOS patients (d) and in normal women at different stages of the menstrual
cycle (e-h). The scatter plots with “r” and “p” values given are the ones with significant correlation coefficients (p < 0.05)
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mid-secretory, and late secretory) showed that miR-23a and
miR-23b reached peak concentrations in the early secretory
phase and were at their lowest level in the late secretory
phase (p < 0.05, Fig. 1a and b). Furthermore, there was a
positive correlation between the expression of miR-23a and
miR-23b in the serum of the healthy controls and in the
subgroup of controls in the proliferative phase (Cv = 142.4
and Cv = 108.9, respectively, p < 0.05, Fig. 1c and e), but
there was no significant correlation between the expression
of the two miRNAs in the women with PCOS (r= 0.3) or
in healthy controls in the mid-secretory (r = −0.1), early
secretory (r = 0.7), or late secretory (r = −0.6) phases.
Body mass index (BMI) and expression of miR-23a/b in
PCOS patients and healthy controls
The BMI in the women with PCOS was higher than in
the healthy controls as a group (Cv = 18.5 vs. Cv = 8.4,
respectively; p = 0.001) and in the proliferative, early
secretory, and late secretory subgroups (p < 0.05, Fig. 2a).
There was a positive correlation between BMI and the
expression of miR-23a in the serum of PCOS patients
(p < 0.05, Fig. 2l), but no such correlation was seen in
any of the healthy controls (p > 0.05). On the other
hand, BMI and serum miR-23b expression showed
significant negative and positive correlations in the
Fig. 2 Body mass index (BMI, kg/m2) (a) in normal women, polycystic ovary syndrome (PCOS) patients, and normal women at different stages of
the menstrual cycle. a,b different superscript letters indicate significant differences between groups (p < 0.05). Correlation of serum miRNA-23a and
miRNA-23b expression with BMI in normal women (a and b), normal women at different stages of the menstrual cycle (c–k), and PCOS patients
(l and m). The scatter plots with “r” and “p” values given are the ones that had significant correlation coefficients (p < 0.05)
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early and late secretory phases in normal women, re-
spectively, (p < 0.05, Fig. 2g and k), but not in the
proliferative or mid-secretory subgroups or in the
PCOS patients (r = 0.4, p = 0.09, Fig. 2m).
Testosterone and expression of miR-23a/b in PCOS
patients and healthy controls
The serum testosterone concentrations in the PCOS pa-
tients were about four times higher than in the healthy
controls (Cv = 31.6 vs. Cv = 46.2, respectively) and in the
four subgroups of healthy controls (p < 0.001, Fig. 3a).
However, there was no correlation between miR-23a or
miR-23b expression and testosterone concentrations in
the serum of the PCOS patients or the healthy con-
trols in any phase of the endometrial cycle (p > 0.05,
Fig. 3b to m).
P4 and E2 and expression of miR-23a/b in healthy controls
Similarly to what has been demonstrated in previous
studies, the serum P4 and E2 concentrations reached
their peak levels in the mid-secretory phase and prolifer-
ative phase, respectively (p < 0.05, Figs. 4a and 5a), and
were at their the lowest concentrations in the proliferative
phase and mid-secretory phase, respectively (p < 0.05).
Fig. 3 Serum testosterone concentrations (a) in normal women, polycystic ovary syndrome (PCOS) patients, and normal women at different stages of the
menstrual cycle. a,b different superscript letters indicate significant differences between groups (p< 0.05). Correlation of serum miRNA-23a and miRNA-23b
expression with testosterone concentrations in normal women (a and b), in normal women at different stages of the menstrual cycle (c–k), and in PCOS
patients (l and m). None of the scatter plots showed significant correlation coefficients (p> 0.05)
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In the healthy controls in the proliferative phase, the
E2 concentrations were negatively correlated with the
expression of miR-23a (p = 0.04, Fig. 5d), but not with
the expression of miR-23b (p > 0.05, Fig. 5e). There
was no correlation between P4 concentration and
miR-23a or miR-23b expression (p > 0.05) in the pro-
liferative phase nor were there any correlations between
E2 and P4 and miR-23a or miR-23b expression in any of
the other phases.
Luteinizing hormone (LH) and follicle stimulating
hormone (FSH) and expression of miR-23a/b in PCOS
patients
The mean and SE values of LH and FSH concentrations
in PCOS patients were 10.8 ± 1.6 ng/mL and 5.9 ±
0.5 ng/mL, respectively, and did not significantly correl-
ate with miR-23a or miR-23b expression (Fig. 6).
Hormones and BMI in healthy controls and PCOS patients
Concentrations of testosterone (r = 0.04), LH (r = −0.06),
and FSH (r = −0.3) did not correlate with BMI in the
PCOS patients (p > 0.05). The correlation coefficients
between testosterone concentrations and BMI were
negative in all four subgroups of healthy women, but
none of the correlations were statistically significant
(p > 0.05). Among the healthy controls, the correlation
coefficients between E2 and P4 concentrations and BMI
were not significant, except for the correlation between
P4 concentrations and BMI in the late secretory phase
(r = 0.71, p = 0.04).
Power of study and odds ratio of effective factors on
PCOS and expression of miR-23a/b
The observed powers of analysis in the risk factors
(miR-23a/b expression, BMI and testosterone concentra-
tions) of PCOS were more than 80% (Table 1).
Fig. 4 Serum progesterone concentrations (a) in normal women at different stages of the menstrual cycle. a,b different superscript letters indicate
significant differences between groups (p < 0.05). Correlation of serum miRNA-23a and miRNA-23b expression with progesterone in normal women
(a and b), in normal women at different stages of the menstrual cycle (c–k), and in PCOS patients (l and m). The scatter plots showed no significant
correlation coefficients (p > 0.05)
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Furthermore, the adjusted odds ratios of the variables fi-
nally included in the logistic model are shown in Tables 2
and 3. Logistic regression analysis indicated significant
effects of the fold changes of miR-23a/b on the likeli-
hood of women with PCOS. The likelihood of women
with PCOS decreased by 0.01-fold for every 1 fold in-
crease of miR-23a expression (P = 0.02; Table 2). On the
other hand, the miR-23b expression on the PCOS was
not significant in the equation (P > 0.05; Table 2).
Without considering the presence or absence of
PCOS, logistic regression analysis indicated significant
negative effects of the testosterone concentrations on
the likelihood of fold changes of miR-23a (Table 3). The
likelihood of more than 1 in fold changes of miR-23a
would be 0.003-fold for each 1 fold decrease in testoster-
one concentration (P = 0.01). While, BMI significant
positive effect was observed only on the likelihood of
fold changes of miR-23b. The likelihood of more than 1
in fold changes of miR-23b would be 1.056-fold for each
1 fold increase in BMI (P = 0.03).
Biological functions of the predicted targets of miR-23a/b
The predicted target genes for miR-23a and miR-23b
were screened in Homo sapiens using the MicroCosm
Targets software. The list of predicted target genes in-
cluded 1078 genes for miR-23a and 1049 genes for
miRNA-23b, from which 377 and 356 target genes,
respectively, were mapped to biological functions and
processes, including hormone synthesis, metabolic
functions, and sexual reproduction. Of these target
genes, the analysis revealed 309 common target genes
for both miR-23a and miR-23b, 68 genes related ex-
clusively to miR-23a, and 47 genes related exclusively
to miR-23b, and these genes are involved in eight
biological processes (Fig. 7).
Fig. 5 Serum estrogen concentrations (a) in normal women at different stages of the menstrual cycle. a,b different superscript letters indicate significant
differences between groups (p < 0.05). Correlation of serum miRNA-23a and miRNA-23b expression with estrogen in normal women (a and b),
in normal women at different stages of the menstrual cycle (c–k), and in PCOS patients (l and m). The scatter plots showed no significant
correlation coefficients (p < 0.05)
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Discussion
We found a negative influence of decrease of miR-23a
on occurrence of PCOS and increase of testosterone. On
the other hand, although a positive effect of BMI on the
expression levels of miR-23b (without considering pres-
ence or absence of PCOS) was observed in logistic re-
gression analysis, but decrease in miR-23b fold-changes
as well as miR-23a decrease was observed in PCOS
women. Considering this fact that miR-23a alterations
was not affected by BMI in contrast with miR-23b, sug-
gests it as a better indicator for evaluation of PCOS than
the miR-23b.
Furthermore, the BMI among the women with PCOS
was higher on average compared with the healthy con-
trols. The mean BMI of healthy women of the same eth-
nicity and in the same age range (20.99 ± 3.31 kg/m2) [6]
is similar to the BMI among healthy controls in the
current study. Therefore, all of the PCOS patients in this
study could be considered to be obese (the mean BMI of
the PCOS patients was 23.96 ± 4.44 kg/m2). Obesity in
the PCOS patients increased the expression of both
miR-23a and miR23b, but BMI was correlated with
decreased expression of these miRNAs in the healthy
controls. The pattern of correlations between obesity
Fig. 6 Correlation of serum miRNA-23a and miRNA-23b expression with luteinizing hormone (LH, a and b) and follicle stimulating hormone
(FSH, c and d) concentrations in PCOS patients. The scatter plots showed no significant correlation coefficients (p > 0.05)
Table 2 Odds ratios of the variables included in the final logistic
regression model for the polycystic ovary syndrome and serum
miRNA-23a and miRNA-23b expression
Variables Odds ratio 95% Confidence interval P-value
miRNA-23a 0.012 0.0–0.46 0.017
miRNA-23b 1.803 0.99–3.54 0.053
Backward likelihood ratio test = 28.57, 2 df, P = 0.0001; Hosmer and Lemeshow
goodness-of-fit test = 2.81, 8 df, P = 0.95; the model fits
Table 1 Observed powers of analysis regarding to different
dependent variables in five groups of normal and polycystic ovary
syndrome women
Variables Observed power (%)
miRNA-23a 100
miRNA-23b 93
Body mass index 95
Testosterone 100
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and the expression of miR-23a and miR23b that was
observed in the present study resembles the pattern of
correlations of serum testosterone, LH, and FSH con-
centrations with the expression of the miR-23a and
miR23b, but the effects of obesity on the relationship
with miR-23a/b expression in the women with PCOS
was greater than the association of hormone changes
with miR-23a/b expression. In the healthy controls and
the endometrial-phase subgroups, obesity and testoster-
one concentrations had negative correlation coefficients,
whereas in the women with PCOS a positive but non-
significant correlation in increased BMI and testoster-
one concentrations was observed. Consistent with our
findings, Murri et al. [7] reported opposite patterns of
association between obesity and testosterone concen-
trations in PCOS patients and healthy controls. According
to the normal range of testosterone levels among healthy
women of the same ethnicity and in the same age range of
the current study (0.32 ± 0.16 ng/mL) [6], all of the PCOS
patients who were selected in this study based on the
Rotterdam consensus criteria were defined as having
hyperandrogenemia (0.59 ± 0.19 ng/mL).
The patterns of changes in the expression of miR-23a
and miR-23b were the same in the PCOS patients and in
the healthy controls and in the endometrial-phase sub-
groups, and in the present study the expressions of both
miR-23a and miR-23b in serum were significantly lower
in the women with PCOS compared to the healthy con-
trols. The one exception was that the mean expression
of miR-23b in the women with PCOS was higher than
that in the healthy controls in the late secretory phase,
and it can be speculated that this difference might be
due to the involvement of miR-23b in ovulation. In sup-
port of this, it has been shown that miR-23b targets the
X-linked inhibitor of apoptosis and can induce apoptosis
in human granulosa cells in vitro [8]. In addition, a com-
parison of seasonally ovulatory and anovulatory follicles
in horses revealed increased expression of miR-23b in
the anovulatory follicles [9]. Furthermore, in our current
work we found that the pattern of expression of miR-
23a and miR-23b changed from a positive correlation in
the proliferative phase to a negative correlation in the
late secretory phase; whereas the women with PCOS
showed a positive correlation in the expressions of miR-
23a and miR-23b.
In the present study, the increase in serum E2 concen-
trations in the proliferative phase was negatively corre-
lated with the expression of miR-23a and miR-23b in the
healthy controls. Furthermore, in the evaluated popula-
tion, a negative influence of increase of testosterone con-
centrations on miR-23a expression was observed. In
addition, the same non-significant effect of testosterone
was observed on miR-23 expression in whole blood. A
previous study on the expression of miR-23a and miR-
23b in follicular fluid showed that expression of these
miRNAs along with the expression of their target gene
could regulate the expression of aromatase, CYP19A1,
in ovarian cells and, therefore, might have a role in E2
biosynthesis [4]. Therefore, it can be speculated that al-
terations in the expression of these miRNAs in serum
might affect follicular growth and ovulation via other
target genes than those that play a role in E2 hormone
synthesis, including target genes that are functionally re-
lated to cell growth and apoptosis. In the present study,
a decrease in miR-23a expression in women with PCOS
was observed, and overexpression of pre-miR-23 has
previously been shown to play a role in apoptosis in
cultured human luteinized granulosa cells [8]. There-
fore, altered miR-23a expression in PCOS patients
might induce down-regulation of apoptotic processes
in ovarian cells.
With the help of bioinformatics tools, we have shown
that miR-23a and miR-23b target large numbers of genes
and that many of these genes are targeted by several
other miRNAs. Target genes of miR-23a and miR-23b
are involved in many biological functions, including
metabolic, cellular, and reproductive processes that are
important in PCOS pathogenesis [2, 10]. One of the
metabolic disorders that has a definite role in PCOS is
obesity [11], and several studies have shown that cellular
communication can be altered in PCOS and obesity, in-
cluding communication between inflammatory cells and
metabolic cells [12–14]. Additionally, inflammatory and
immune gene targets that regulate cellular processes
such as apoptosis can influence follicular function and
steroid production [10, 15].
The major limitation of the present study was pos-
sibly the evaluation of serum miRNA expression, which
represents miRNAs from several unknown origin cell
types. However, several studies have highlighted the po-
tential of serum samples to act as developmental
markers of diseases, including PCOS [7, 16–18]. There-
fore, sampling of serum might represent the overall
Table 3 Odds ratios of the variables included in the final logistic
regression model for the serum miRNA-23a or miRNA-23b
expression and body mass index and testosterone concentration
Variables Odds ratio 95% Confidence interval P-value
miRNA-23a
Body mass index 1.051 0.99–1.11 0.08
Testosterone 0.003 0.00–0.24 0.01
miRNA-23b
Body mass index 1.056 1.01–1.11 0.03
Testosterone 0.100 0.01–1.47 0.09
miRNA-23a: Backward likelihood ratio test = 14.08, 2 df, P = 0.001; Hosmer and
Lemeshow goodness-of-fit test = 18.67, 8 df, P = 0.02; the model fits
miRNA-23b: Backward likelihood ratio test = 5.17, 2 df, P = 0.08; Hosmer and
Lemeshow goodness-of-fit test = 8.47, 8 df, P = 0.39; the model fits
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state of the entire body instead of specific cells at the
time of collection.
Conclusions
The present research showed lower concentrations of
miR-23a and miR-23b in the serum of PCOS patients
compared to healthy controls. Furthermore, we demon-
strated the positive influence of obesity on the serum ex-
pression of miR-23b related to metabolic and cell
function disorders. In addition, testosterone had negative
effects on the levels of circulating miR-23a. Exploring
the target genes and pathways of miR-23a/b and other
differentially expressed miRNAs will contribute to a
better understanding of the roles of miRNAs in the
pathogenesis of PCOS. In terms of new biomarkers for
the detection of PCOS in patients, miR-23a might be a
better choice, but the correlation between the levels of
these miRNAs in the serum and in the follicular cells
needs further investigation.
Methods
Subjects and selection criteria
In the current study, 18 Han Chinese women (with a
mean ± SD age of 25.8 ± 4.5 years) were recruited from
the Affiliated Obstetrical and Gynecological Hospital
of Fudan University between September 2011 and
Fig. 7 Mapping of target genes that were common to miRNA-23a (blue nodes), miRNA-23b (yellow nodes), or both miRNAs (green nodes) to
biological processes (grey nodes). The landscape of genes was mapped to biological processes and visualized using the Cytoscape 3.4.0 software
[21]. The lengths of the edges show the relative scores for the effects of the miRNAs on the target genes according to the MicroCosm
Targets software
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January 2012. The women were all diagnosed with
PCOS based on the revised diagnostic criteria an-
nounced in the Rotterdam consensus [1], and patients
with Cushing syndrome, late-onset congenital adrenal
hyperplasia, thyroid dysfunction, hyperprolactinemia,
or androgen-secreting tumors were excluded. Other
exclusion criteria included diabetes, hypertension,
chronic renal disease, smoking, and the use of alcohol
or medications. Thirty healthy age-matched Han Chinese
women (25.5 ± 2.3 years old) with no previous history of
reproductive system diseases or appendicitis served as
controls. The control women had normal and regularly
cycling menstrual periods, and their ovaries appeared nor-
mal on ultrasound. The exclusion criteria of the healthy
women in the study were taking drugs, including oral con-
traceptives or other hormone drugs, intrauterine device
placement, smoking, and/or pregnancy in the past 3
months. Control subjects were divided into four groups
according to their endometrial cycle phase – prolifer-
ative phase (days 4–14, n = 8), early secretory phase
(days 15–18, n = 6), mid-secretory phase (days 19–24,
n = 8), and late secretory phase (days 25–30, n = 8).
Assessment of BMI and sex hormones
The BMI in both normal women and PCOS patients
was calculated as weight (kg) divided by the square of
the height (m2). Measurements and blood samples were
conducted within the first 10 days from the onset of
menstruation in PCOS cases with mild oligomenorrhea,
and they were conducted at random times for PCOS cases
with severe oligomenorrhea or amenorrhea. Measure-
ments and blood samples were conducted at different
phases of the endometrial cycle in controls as described
above. Total testosterone, LH, and FSH were measured by
radioimmunoassay (RigorBio Scientific and Technology
Co., Beijing) according to the manufacturer’s instructions.
Quantification of miR 23a/b in peripheral blood
Venous blood samples (5 ml) were drawn from every
subject. Serum was separated by centrifuging at 3000 × g
for 10 min at 4 °C and was stored at −20 °C. Whole
RNA was extracted from 200 μL of serum with the miR-
cute miRNA Isolation kit (DP501, Tiangen Biotech,
Beijing) according to the manufacturer’s instructions.
The RNA was then reverse transcribed using the miR-
cute miRNA first-strand cDNA synthesis kit (KR201,
Tiangen Biotech, Beijing), and quantitative real-time
polymerase chain reaction (qPCR) was performed using
the miRcute miRNA qPCR detection kit (Tiangen
Biotech, Beijing). The qPCR was performed under the
following conditions: initial PCR denaturation at 94 °C
for 120 s followed by 42 combined cycles of denatur-
ation of 20 s at 94 °C and annealing and extension of
34 s at 60 °C. Fluorescence was measured at 55 °C in
81 cycles of 10 s. Results were calculated using the 2−ΔΔCt
method, and U6 was used as the controls for miR-23a and
miR-23b. The sequences of primers were as follows
(Invitrogen, Shanghai):
Primer sequence of miR-23a: 5′-ATCACATTGCCA
GGGATTTCCA-3′
Primer sequence of miR-23b: 5′-GCACATTGCCA
GGGATTACCA-3′
U6 as the internal control: 5′-CTCGCTTGGGCAGC
ACA-3
Statistical analysis
Data are described as the mean ± SD. An independent
sample t-test or one-way ANOVA with correction of p-
values with the Bonferroni post-hoc test was used to test
for differences in demographic variables and laboratory
measurements between PCOS patients and healthy con-
trols. Spearman correlation coefficients were calculated
to evaluate the relationship between miRNA levels and
other measurements in both the PCOS and control
groups. All data were analyzed using SPSS version 22.0
(SPSS, Inc., Chicago, IL), and p < 0.05 was considered
statistically significant.
To evaluate the power of study regarding to the se-
lected sample size and the five groups of normal and
PCOS women, the observed power of the dependent
variables (miR-23a/b expression, BMI and testosterone
concentrations) were estimated using univariate analysis
of variance in general linear model of SPSS [19].
Possible effects of the miR-23a and miR-23b on occur-
rence of PCOS were explored using logistic regression
analysis. The data of the normal women was used as
reference. The data were compared by logistic regression
analysis using the presence of PCOS as the dependent
variable (0 denotes normal and 1 denotes PCOS) and
the expression of miR-23a and the expression of miR-
23b as the independent factors were entered into equa-
tion. Furthermore, possible effects of the BMI and serum
testosterone concentration on the fold change of miR-
23a and miR-23b were explored using logistic regression
analysis. The data of the fold change of miR-23a/b less than
1 was used as reference. The data were compared by logis-
tic regression analysis using the fold change of miR-23a or
miR-23b as the dependent variable (0 denotes less than 1
fold change and 1 denotes more than or equal 1 fold
change) and the BMI and serum testosterone, concentra-
tion as the independent factors were entered into equation.
Regression analyses were conducted according to the
method of Hosmer and Lemeshow [20]. The p-values for
data inclusion and exclusion were set at 0.05 and 0.10, re-
spectively. The variable that had been selected or retained
entered the final likelihood ratio (LR), in which the final
odds ratio estimates with 95% confidence intervals were
derived. The constants were not included in the model.
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